Psoriasis is a systemic chronic skin disorder characterized by excessive keratinocyte proliferation that results into thickened scaly plaques, itching and inflammatory changes in the epidermis and dermis. It is transmitted genetically but can be provoked by environmental factors.
It is found in approximately 2% of the population that primarily affects the skin and joints.
It is associated with other inflammatory disorders and autoimmune diseases (eg psoriatic arthritis, inflammatory bowel disease, coronary artery disease).
Generally, it begins as red scaling papules that coalesce to form round-to-oval plaques. The rashes are often pruritic and may be painful.
More patients with moderate-to-severe psoriasis who were treated with the tyrosine kinase 2 (TYK2) inhibitor BMS-986165 achieved improvements in their condition compared with placebo recipients, according to a recent phase II study.
Two phase III studies have demonstrated the superiority of the selective interleukin-23p19 inhibitor risankizumab over ustekinumab or placebo in helping patients with moderate-to-severe chronic plaque psoriasis reduce the severity of their condition.
An association exists between stress and quality of life (QoL) in patients with psoriasis vulgaris, according to a poster presented at the 23rd Asian-Australasian Regional Conference of Dermatology (RCD 2018) held in Surabaya, Indonesia.
Interleukin 17A (IL-17A) inhibitors show better efficacy than ustekinumab in achieving clearance in adults with moderate-to-severe plaque psoriasis, a recent study has shown. Additionally, IL-17A inhibitors are generally more effective than etanercept, adalimumab and apremilast.
New drug applications approved by US FDA as of 16 - 31 March 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvalsmay have occurred since the original approval date.
The approved psoriasis therapy ustekinumab also reduces aortic vascular inflammation, along with improved psoriasis severity, compared with placebo in patients with moderate-to-severe psoriasis, according to the VIP-U* study presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, US.
In patients with psoriasis, ocular surface involvement implies the need for periodic ophthalmological examinations to diagnose the condition and allow proper treatment, which may help improve the patients’ quality of life, suggests a recent study.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.